 SAN CARLOS, Calif., Nov. 10, 2020 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a pioneer and global leader in cell-free DNA testing, today announced it will present new immunotherapy data on its personalized and tumor-informed molecular residual disease MRD assay, Signatera, at the... 